| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Iterum Therapeutics Plc (ITRM) has 2 insiders with recent SEC Form 4 filings, including 6 buys and 10 sells. ITRM is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 241.0K | $7.2K | - | |
| Other | 200.0K | $6.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2025 | Dunne Michael W. | Director | Buy | 6,000 | $0.37 | $2,191.20 | +2.6% | -35.3% | - | |
| Aug 8, 2025 | Dunne Michael W. | Director | Buy | 15,000 | $0.72 | $10,854.00 | +6.8% | -18.0% | - | |
| Dec 22, 2023 | Dunne Michael W. | Director | Buy | 25,000 | $1.40 | $35,000.00 | +28.2% | +12.9% | +26.4% | |
| Dec 18, 2023 | Dunne Michael W. | Director | Buy | 10,000 | $1.84 | $18,442.00 | +12.7% | -6.3% | +5.2% | |
| Nov 22, 2023 | Dunne Michael W. | Director | Buy | 20,000 | $2.03 | $40,690.00 | +34.0% | -29.0% | -14.5% | |
| Nov 20, 2023 | Fishman Corey N. | Chief Executive Officer | Buy | 10,000 | $1.59 | $15,863.00 | +22.5% | +6.5% | +10.1% | |
| Dec 2, 2022 | Puttagunta Sailaja | Chief Medical Officer | Sale+OE | 3,365 | $1.32 | $4,441.80 | -40.4% | -17.3% | +52.5% | |
| Sep 20, 2022 | Ahrens Brenton Karl88 | Director | Sell | 37,246 | $1.82 | $67,930.20 | -55.8% | -44.2% | -59.4% | |
| Sep 15, 2022 | Ahrens Brenton Karl88 | Director | Sell | 45,000 | $2.09 | $93,846.00 | -22.3% | -43.0% | -61.0% | |
| Sep 12, 2022 | Ahrens Brenton Karl88 | Director | Sell | 33,298 | $2.31 | $76,802.52 | -10.2% | -49.8% | -65.3% |